Thromnoembolic episodes in patients affected by COVID-19

• Autor(a) principal: Morais Viana, Liz Stéfanie
• Data de Publicação: 2022
• Outros Autores: Medina, Laura Pimentel, Araujo, Selenna Gualberto de, Falcão, João Marcelo Junio Gomes, Cordeiro, Nikolle Poleto Vasconcelos, Rodrigues, Marta Cristina da Cunha
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Científica da Faculdade de Medicina de Campos
• Texto Completo: https://www.fmc.br/ojs/index.php/RCFMC/article/view/669
• topic: COVID-19; SARS-CoV-2; Trombose; COVID-19; SARS-CoV-2; Thrombosis

COVID-19 is defined as a severe respiratory disease with high transmissibility and virulence, with SARS-CoV-2 as the causative virus. The host's defense mechanisms include pro-inflammatory cytokines and complement system proteins, which are responsible for relaying the cycle of inflammation and thrombosis, since they activate the coagulation cascade. To understand the Covid-19 pathway and the interaction of the disease with immunity, endothelium, and coagulation, as well as the possibleprogression to the unfolding thromboembolic disease. Data collection in SciELO, PubMed, ScienceDirect platforms regarding thromboembolic episodes in patientsaffected by COVID-19, published from 2014, using age criteria between 40 and 80 years and excluding repeatedstudies. Among the most common thromboembolic events observed in patients with Covid-19 is venousthromboembolism (VTE). Thrombotic manifestations may arise during or after the course of infection. The infection initially develops inflammation and activation of the coagulation cascade in a localized manner, however, with disease progression and further development of defense mechanisms in the body, a possible disseminated intravascular coagulopathy (DIC) may occur. Patients with more severe disease have a greater chance of developing a coagulopathy associated with a poor prognosis, and are therefore more likely to develop thrombotic events. Moreover, individuals who already had chronic inflammatory comorbidities, such as diabetes, heart and lung diseases, are more susceptible to complications.